MTPConnect’s TTRA Program Delivering Strong Health and Economic Impact at Halfway Mark
Posted: 27 February 2024 A new report published today shows MTPConnect’s Targeted Translation Research Accelerator (TTRA) program for diabetes and cardiovascular disease is already delivering benefits and novel health solutions for Australian patients and the health sector – just over halfway…
INOVIQ DETECTS 19% MORE BREAST CANCERS THAN LEADING TEST
Posted: 27 February 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is excited to announce the successful completion of its breast cancer study. In a 2023 clinical validation study (n=483), INOVIQ’s SubB2M/CA15-3 test detected over 80% of breast cancers across…
Nanodiamonds could hold key to cool clothing
Posted: 21 February 2024 Researchers from RMIT University are using nanodiamonds to create smart textiles that can cool people down faster. The study found fabric made from cotton coated with nanodiamonds, using a method called electrospinning, showed a…
Ultrasound jolts lazy sperm to life, offering hope in male infertility
Posted: 21 February 2024 Exposing “lazy” human sperm to ultrasound can increase their swimming activity more than three-fold and improve the success rate of assisted reproduction, a new study has found. Engineering researchers at Monash University have shown…
$50 million to develop world-leading artificial heart
Posted: 21 February 2024 The Australian Government is providing $50 million to develop and commercialise the world’s most advanced artificial heart, a technology that could halve deaths from heart failure globally and contribute $1.8 billion to Australia and…
VivaGel BV US FDA Appeal Outcome
Posted: 20 February 2024 Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has completed the formal dispute resolution process with the US Food and Drug Administration (FDA) in relation to VivaGel® BV. The FDA has maintained its position that…
Effort to cure corneal blindness globally welcomes $35 million support
Posted: 20 February 2024 University of Melbourne researchers addressing the global challenge of corneal blindness – caused by disorders that damage and scar the transparent layer of our eyes – have welcomed a $35 million grant from the…
Major discovery points to more potent, durable RNA-based therapeutics
Posted: 20 February 2024 Australian scientists have made a major discovery that could underpin the next generation of RNA-based therapeutics, and lead to more potent and longer-lasting RNA-based drugs with an even wider array of potential uses. In…
Brandon Biocatalyst in partnership with ANDHealth selected by Federal Government to deliver $50m dementia and cognitive decline incubator
Posted: 20 February 2024 Brandon BioCatalyst’s CUREator, in partnership with ANDHealth, is set to deliver a BioMedTech Incubator (BMTI) focused on developing research discoveries and medical innovations with commercial potential to address dementia and cognitive decline thanks…
Breakthrough heralds immune-personalised medicine for lupus
Posted: 20 February 2024 The immune system is extraordinarily complex and powerful, the primary function of which is to detect and destroy foreign or “non-self” proteins, including infections and cancer. To do this, it’s evolved two parallel sets…
Innovative modelling may help breast cancer patients who don’t respond to treatment
Posted: 20 February 2024 Monash University-led research is using maths to predict how new combination therapies can help patients with breast cancer who no longer respond to conventional therapies. Published in NPJ Precision Oncology , the Monash Biomedicine Discovery Institute (BDI) study…
Immutep appoints Anne Anderson to Board
Posted: 20 February 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announces the appointment of Anne Anderson as independent non-executive director (NED)…
